2cureX AB (publ) 2CUREX.ST Stock
0.38 SEK
{{ price }}
4.395605%
{{change_pct}}%
SECTOR
Healthcare
INDUSTRY
Biotechnology
COUNTRY
Sweden
Exchange
Stockholm
Market Cap
6.69M SEK
LOW - HIGH [24H]
0.36
-
0.4 SEK
VOLUME [24H]
101.4K SEK
{{ volume }}
P/E Ratio
0
Earnings per share
-1.87 SEK
2cureX AB (publ) Price Chart
2cureX AB (publ) 2CUREX.ST Financial and Trading Overview
| 2cureX AB (publ) stock price | 0.38 SEK |
| Previous Close | 5.14 SEK |
| Open | 4.84 SEK |
| Bid | 5 SEK x 0 |
| Ask | 5.1 SEK x 0 |
| Day's Range | 4.84 - 5.12 SEK |
| 52 Week Range | 4.83 - 12.5 SEK |
| Volume | 5.31K SEK |
| Avg. Volume | 17.8K SEK |
| Market Cap | 89.77M SEK |
| Beta (5Y Monthly) | 0.777777 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.87 SEK |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
2CUREX.ST Valuation Measures
| Enterprise Value | 56.71M SEK |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 24.074762 |
| Price/Book (mrq) | 2.5160336 |
| Enterprise Value/Revenue | 15.207 |
| Enterprise Value/EBITDA | -1.762 |
Trading Information
2cureX AB (publ) Stock Price History
| Beta (5Y Monthly) | 0.777777 |
| 52-Week Change | -55.68% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 12.5 SEK |
| 52 Week Low | 4.83 SEK |
| 50-Day Moving Average | 6.48 SEK |
| 200-Day Moving Average | 7.98 SEK |
2CUREX.ST Share Statistics
| Avg. Volume (3 month) | 17.8K SEK |
| Avg. Daily Volume (10-Days) | 12.88K SEK |
| Shares Outstanding | 17.6M |
| Float | 10.91M |
| Short Ratio | N/A |
| % Held by Insiders | 55.65% |
| % Held by Institutions | 0.49% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -871.35% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -37.53% |
| Return on Equity (ttm) | -57.50% |
Income Statement
| Revenue (ttm) | 3.73M SEK |
| Revenue Per Share (ttm) | 0.21 SEK |
| Quarterly Revenue Growth (yoy) | 82.89% |
| Gross Profit (ttm) | 3.37M SEK |
| EBITDA | -32182000 SEK |
| Net Income Avi to Common (ttm) | -29448000 SEK |
| Diluted EPS (ttm) | -1.57 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 34.83M SEK |
| Total Cash Per Share (mrq) | 1.98 SEK |
| Total Debt (mrq) | 0 SEK |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 12.961 |
| Book Value Per Share (mrq) | 2.027 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -28569000 SEK |
| Levered Free Cash Flow (ttm) | -16456125 SEK |
Profile of 2cureX AB (publ)
| Country | Sweden |
| State | N/A |
| City | Copenhagen |
| Address | Fruebjergvej 3 |
| ZIP | 2100 |
| Phone | 45 22 11 53 99 |
| Website | https://www.2curex.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 14 |
2cureX AB (publ) operates as a medtech company in Europe. The company's principal product is IndiTreat, an IVD test, which helps to predict cancer patient's response and resistance to different drugs and select the appropriate treatment. It is also conducting various clinical programs for IndiTreat for colorectal, ovarian, and pancreatic cancers. The company was incorporated in 2006 and is based in Copenhagen, Denmark.
Q&A For 2cureX AB (publ) Stock
What is a current 2CUREX.ST stock price?
2cureX AB (publ) 2CUREX.ST stock price today per share is 0.38 SEK.
How to purchase 2cureX AB (publ) stock?
You can buy 2CUREX.ST shares on the Stockholm exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for 2cureX AB (publ)?
The stock symbol or ticker of 2cureX AB (publ) is 2CUREX.ST.
Which industry does the 2cureX AB (publ) company belong to?
The 2cureX AB (publ) industry is Biotechnology.
How many shares does 2cureX AB (publ) have in circulation?
The max supply of 2cureX AB (publ) shares is 17.6M.
What is 2cureX AB (publ) Price to Earnings Ratio (PE Ratio)?
2cureX AB (publ) PE Ratio is now.
What was 2cureX AB (publ) earnings per share over the trailing 12 months (TTM)?
2cureX AB (publ) EPS is -1.87 SEK over the trailing 12 months.
Which sector does the 2cureX AB (publ) company belong to?
The 2cureX AB (publ) sector is Healthcare.
2cureX AB (publ) 2CUREX.ST included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| First North Sweden SEK GI FNSESEKGI | 1956.89 SEK 191.02 USD |
-0.28
|
— — | — — | — — | — - | — — |
| First North Sweden EUR GI FNSEEURGI | 1570.14 EUR 1716.38 USD |
-0.77
|
— — | — — | — — | — - | — — |
| First North Health Care GI FN20GI | 917.04 EUR 1002.44 USD |
-1.17
|
— — | — — | — — | — - | — — |
| First North All-Share EUR FIRSTNORTHEUR | 97.9 EUR 107.01 USD |
-0.64
|
— — | — — | — — | — - | — — |
| First North Sweden SEK PI FNSESEKPI | 1843.91 SEK 179.99 USD |
-0.28
|
— — | — — | — — | — - | — — |
| First North Sweden EUR PI FNSEEURPI | 1479.5 EUR 1617.29 USD |
-0.77
|
— — | — — | — — | — - | — — |
| First North Health Care PI FN20PI | 912.9 EUR 997.92 USD |
-1.17
|
— — | — — | — — | — - | — — |
| First North All-Share SEK FIRSTNORTHSEK | 123.34 SEK 12.04 USD |
-0.14
|
— — | — — | — — | — - | — — |
| First North All-Share DKK FIRSTNORTHDKK | 97.96 DKK 14.36 USD |
-0.62
|
— — | — — | — — | — - | — — |
- {{ link.label }} {{link}}